SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
-3.68%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.12B
AUM Growth
+$1.12B
(-5.6%)
Cap. Flow
+$30.4M
Cap. Flow
% of AUM
2.7%
Top 10 Holdings %
Top 10 Hldgs %
66.5%
Holding
70
New
11
Increased
15
Reduced
11
Closed
12
Top Buys
| 1 |
Merck
MRK
|
$32.9M |
| 2 |
Novo Nordisk
NVO
|
$30.5M |
| 3 |
iRhythm Technologies
IRTC
|
$15.4M |
| 4 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$15.2M |
| 5 |
Sanofi
SNY
|
$14.1M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$21.9M |
| 2 |
Zoetis
ZTS
|
$20.1M |
| 3 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$18.3M |
| 4 |
Guardant Health
GH
|
$15.9M |
| 5 |
AstraZeneca
AZN
|
$15.7M |
Sector Composition
| 1 | Healthcare | 98.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $262M | 21.84% |
2,073,124
+120,047
| +6% | +$15.2M |
|
2
Natera
NTRA
$23.2B
| $110M | 9.16% |
3,102,960
| – | – |
|
|
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $105M | 8.75% |
5,573,949
| – | – |
|
|
JBIO
4
Jade Biosciences, Inc. Common Stock
JBIO
$249M
| $58.7M | 4.89% |
3,758,686
| – | – |
|
5
Ascendis Pharma
ASND
$12.1B
| $46.5M | 3.87% |
499,824
| – | – |
|
6
Vera Therapeutics
VERA
$1.44B
| $43.3M | 3.61% |
3,181,442
| – | – |
|
7
Y-mAbs Therapeutics
YMAB
$389M
| $33.2M | 2.76% |
2,194,278
| – | – |
|
|
8
Merck
MRK
$214B
| $32.9M | 2.74% |
+360,961
| New | +$32.9M |
|
|
9
Novo Nordisk
NVO
$251B
| $30.5M | 2.54% |
+273,873
| New | +$30.5M |
|
|
10
United Therapeutics
UTHR
$18.3B
| $25.1M | 2.09% |
106,379
-92,804
| -47% | -$21.9M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.3B
| $25M | 2.08% |
301,605
+125,072
| +71% | +$10.4M |
|
|
RETA
12
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $23.8M | 1.98% |
783,851
+181,306
| +30% | +$5.51M |
|
13
Vertex Pharmaceuticals
VRTX
$103B
| $21.1M | 1.75% |
74,758
-20,245
| -21% | -$5.7M |
|
|
14
AstraZeneca
AZN
$249B
| $20.9M | 1.74% |
316,360
-237,543
| -43% | -$15.7M |
|
15
Regenxbio
RGNX
$461M
| $19.2M | 1.6% |
776,624
+162,539
| +26% | +$4.01M |
|
|
INZY
16
DELISTED
Inozyme Pharma
INZY
| $17.4M | 1.45% |
3,655,308
+1,627,000
| +80% | +$7.76M |
|
|
CTIC
17
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $16.1M | 1.34% |
2,704,510
+751,819
| +39% | +$4.49M |
|
|
CCXI
18
DELISTED
ChemoCentryx, Inc.
CCXI
| $15.8M | 1.31% |
636,659
+62,975
| +11% | +$1.56M |
|
|
19
iRhythm Technologies
IRTC
$5.5B
| $15.4M | 1.28% |
+142,091
| New | +$15.4M |
|
|
20
Sanofi
SNY
$121B
| $14.1M | 1.18% |
+282,200
| New | +$14.1M |
|
21
DexCom
DXCM
$29.1B
| $14.1M | 1.17% |
189,092
+148,827
| +370% | +$11.1M |
|
22
Cytokinetics
CYTK
$5.94B
| $12.6M | 1.05% |
320,780
+257,836
| +410% | +$10.1M |
|
23
NextCure
NXTC
$13.2M
| $12.6M | 1.05% |
2,671,856
| – | – |
|
24
Immatics
IMTX
$649M
| $11.3M | 0.94% |
1,294,103
+26,040
| +2% | +$227K |
|
|
RXDX
25
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $10.9M | 0.91% |
+386,395
| New | +$10.9M |
|